Results 151 to 160 of about 7,633 (200)
Some of the next articles are maybe not open access.
The Association of Mesalamine With Kidney Disease
Advances in Chronic Kidney Disease, 2020The package inserts for products containing 5-aminosalicylic acid, or mesalamine, include the following language regarding the risk of adverse kidney effects: "renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and rarely renal failure, has been reported in patients given products such as mesalamine ...
Avinash, Adiga, David S, Goldfarb
openaire +2 more sources
Mesalamine in Ulcerative Colitis
DICP, 1991Sulfasalazine has been used for many years in the management of ulcerative colitis. As many as 20 percent of patients treated with it experience intolerable adverse effects usually attributed to its sulfapyridine component. The other active component is 5-aminosalicylic acid (5-ASA); the only 5-ASA enema preparation currently available in the U.S.
J M, Fitzgerald, T D, Marsh
openaire +2 more sources
Mesalamine-Induced Granulomatous Hepatitis
American Journal of Gastroenterology, 1999A 42-yr-old man with ulcerative colitis was admitted for investigation of prolonged fever associated with cholestatic liver tests. Endoscopic retrograde cholangiopancreatography demonstrated a normal biliary tree, and liver biopsy showed granulomata.
M, Braun +4 more
openaire +2 more sources
MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
Digestive and Liver DiseaseMedical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed mucosa to exert its therapeutic action.
Ferdinando, D'Amico +3 more
openaire +2 more sources
Reviews in gastroenterological disorders, 2006
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source
Connecticut medicine, 2010
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Multicenter Survey on Mesalamine Intolerance in Patients With Ulcerative Colitis
Journal of Gastroenterology and Hepatology (Australia), 2021Akiko Fujiwara, Jun Kato, Reiji Higashi
exaly

